ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Kaempferol inhibited pyroptosis in preeclampsia by modulating the NLRP3 inflammasome through the STAT3-associated mitophagy pathway.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Preeclampsia (PE) is driven by placental dysfunction, where oxidative stress triggers mitochondrial damage. Damaged mitochondria, in turn, activate the NLRP3 inflammasome, leading to cell pyroptosis and exacerbating placental injury. Kaempferol (KAE), a natural flavonol with antioxidant properties, whether it acts by enhancing mitochondrial clearance to interrupt this damaging cycle, remains unknown. We employed an L-NAME-induced PE rat model and a cellular hypoxia/reoxygenation model using HTR-8/SVneo trophoblasts. KAE's effects were evaluated by monitoring clinical symptoms, placental histology, oxidative stress (DHE staining, MitoSOX), and key protein expression (Western blot, ELISA). The involvement of mitophagy was assessed through detection of PINK1 and Parkin. STAT3 subcellular localization was examined by fractionation, and its functional role was validated using STAT3 siRNA knockdown. Pyroptosis was evaluated by GSDMD-N cleavage, LDH release assay, and propidium iodide (PI) uptake. The specific roles of STAT3 signaling and mitophagy in the therapeutic effects of KAE were investigated using Stattic (STAT3 inhibitor) and Mdivi-1 (mitophagy inhibitor). KAE treatment dose dependently alleviated maternal hypertension, proteinuria, and fetal growth restriction in PE rats. Mechanistically, KAE reduced oxidative stress, restored autophagy flux (increased LC3-Ⅱ/LC3-Ⅰ; decreased p62), upregulated mitophagy-specific markers PINK1 and Parkin, promoted STAT3 phosphorylation and its mitochondrial translocation, and suppressed NLRP3 inflammasome activation and pyroptosis. KAE promoted STAT3 phosphorylation. In vitro, the protective effects of KAE on cell function were reversed by Stattic and Mdivi-1. Stattic blocked KAE's action on STAT3, mitophagy, and pyroptosis, while Mdivi-1 only reversed its effects on mitophagy and downstream pyroptosis without affecting STAT3 activation. STAT3 knockdown confirmed its essential role in KAE-induced mitophagy enhancement and pyroptosis suppression. KAE ameliorates PE through a STAT3-associated mechanism involving enhanced mitophagy, thereby inhibiting NLRP3-driven pyroptosis and improving trophoblast function. This study identifies a STAT3-associated mitophagy pathway as a potential therapeutic target in PE.
Indexed as
Identifiers
41964672What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.